Resources
Did you mean
Schering-Plough Corp. (14 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Is Merck Hanging Schering Out to Dry on Vytorin?
- Is Merck Hanging Schering Out to Dry on Vytorin?VytorinPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-07-07
- Schering-Plough Now in the Feds' Crosshairs
- Schering-Plough Now in the Feds' CrosshairsThe Great Disappointment of EthicsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and...
- Discussion threads 2008-07-10
- How Pharma Stacks the Deck with Medical Journals
- How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-06-18
- Schering's CEO, a Failed Trial and $16 Million
- Forbes' Matthew Herper and Michael Maiello have just jumped on a subject we alluded to -- perhaps too obliquely -- a few weeks back in discussing the eye-popping $30 million Schering-Plough CEO Fred Hassan pulled down in 2007. Not only did Schering post a $1.5 billion loss that year, it...
- Blog posts 2008-05-20
- Fred Hassan, Schering's $30 Million Man
- Schering-Plough has had a fairly miserable year so far, thanks to its apparent efforts to keep bad scientific news about the cholesterol pill Vytorin out of the public eye. CEO Fred Hassan, however, is still living off last year's glory -- even if it might well have been far less...
- Blog posts 2008-04-24
- Is Merck Hanging Schering Out to Dry on Vytorin?
- A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin. Vytorin, of course, is a combination...
- Blog posts 2008-04-23
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
Additional Resources
- Zacks Analyst Blog Highlights: El Paso Corp., Akzo Nobel N.V., Schering-Plough Corp., Moneygram International, Inc. and PMC-Sierra, Inc
- CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: El Paso Corp. (NYSE: EP), Akzo Nobel N.V. (OTC: AKZOY), Schering-Plough...
- Articles 2008-07-09
- Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
- Corifollitropin alfa meets primary endpoints in ENGAGE Trial KENILWORTH, N.J., July 8 /PRNewswire-FirstCall/ -- Schering-Plough Corp., announced today that corifollitropin alfa, its experimental, sustained follicle stimulant SFS met its primary endpoints in the Phase III ENGAGE trial, according to data presented during a Schering-Plough-sponsored symposium at...
- Articles 2008-07-08
- Seven Summits Research Releases Comments on INTC, X, AET, VIP, and SGP
- CHICAGO, July 3 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks. Seven Summits Strategic Investments NewsBites are available to all investors at: http://www.go7now.com/nb/0703Y (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's Seven...
- Articles 2008-07-03
- Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
- KENILWORTH, N.J., July 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today announced the successful closing of its previously announced transaction with Virbac, S.A. to divest animal health products from selected franchises. These divestments were requested by the European Commission as part of its October 2007 clearance of the acquisition...
- Articles 2008-07-02
- SEX DOCTOR: KNOW YOUR HORMONES
- MORE than 3.5 million women in the UK take the combined oral contraceptive every day. But how much do you know about the pill you're taking? Research by Bayer Schering Pharma compared how much women know about their dietary intake with how much they know about their pill - and...
- Articles 2008-06-29
- Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
- KENILWORTH and WHITEHOUSE STATION, N.J., June 27 /PRNewswire-FirstCall/ -- Schering-Plough Corp. and Merck & Co., Inc. announce the withdrawal of the New Drug Application NDA for the loratadine/montelukast combination tablet. The companies also terminated the Schering-Plough/Merck Pharmaceuticals respiratory joint venture, which was formed in May...
- Articles 2008-06-27
- BioPharm America™ Features Top Industry Decision-Makers in Life Science Partnering
- CARLSBAD, Calif. and ATLANTA -- Navigating a shifting landscape of bio-pharma deal making will be the focus for discussions among licensing and business development executives from Bayer Schering, Novo Nordisk, Novartis, Pfizer, Johnson & Johnson and Shire Pharmaceuticals at BioPharm America[TM] in Atlanta, September 9-10, 2008. The backdrop...
- Articles 2008-06-25
- Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
- KENILWORTH, N.J., June 24 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Aug. 26, 2008, to shareholders of record at the close of business on Aug. 1, 2008. As...
- Articles 2008-06-24
- Titan Pharmaceuticals Announces Spheramine® Presentations at 12th International Congress of Parkinson's Disease and Movement Disorders
- Five-Year Update of Pilot Study Shows Spheramine Reduces Severity and Frequency of Parkinson's Symptoms While Also Improving Health-Related Quality of Life CHICAGO & SOUTH SAN FRANCISCO -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that Spheramine[R], the company's novel cell-based therapy being developed in collaboration with Bayer Schering Pharma...
- Articles 2008-06-24
- VIVALIS GRANTS RIGHTS TO EBx(R) CELL LINE FOR TESTING IN PRODUCTION OF VIRAL VACCINES
- - VIVALIS announced today that ithas signed a research license with an animal health companyundisclosed, to evaluate EBx® cell line (EB66) for theproduction of several viral vaccines. The world-wide veterinary vaccine market was 1.5 billion USD in2007. VIVALIS has already licensed its EBx® platform to majoractors in the field including:...
- Articles 2008-06-18
- CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin® FIT Trial Data for Potential U.S. Supplemental Marketing Application
- Access to data may provide potential for label expansion in the U.S. SEATTLE, June 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. CTI (Nasdaq: CTIC; MTA) announced today an agreement with Bayer Schering Pharma to gain access to Bayer's phase III ZevalinR ([90Y]-ibritumomab tiuxetan) First-line Indolent Trial, FIT data....
- Articles 2008-06-18
- Cell Therapeutics, Inc. to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin® FIT Trial Data
- SEATTLE, June 18 /PRNewswire-FirstCall/ -- On Wednesday, June 18, 2008, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s CTI (Nasdaq: CTIC; MTA) management team will host a conference call to discuss agreement with Bayer Schering Pharma for access to Phase III ZevalinR FIT...
- Articles 2008-06-18
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
